Figure 4
From: COX-2/VEGF-Dependent Facilitation of Tumor-Associated Angiogenesis and Tumor Growth in vivo
Effects of cyclo-oxygenase (COX) inhibitors on tumor-associated angiogenesis. (A) Typical appearance of tumors. A suspension of sarcoma 180 cells was injected into the subcutaneous tissue of ddy mice. COX inhibitors (mofezolac, NS-398, JTE-522, and aspirin, each at a dose of 10 mg/kg) were separately administered orally as suspensions (0.05 ml per 10 g of body mass) every 12 hours beginning on the day of cell implantation and continuing throughout the 14-day experimental period. Tumors were then dissected and photographed. (B) Correlation between the microvessel density and the hemoglobin content of tumor tissue. (C) Effects of COX inhibitors on tumor-associated angiogenesis at the end of the 14-day experimental period. Data are means ± sem for the numbers of tumors indicated in parentheses. *p < 0.05 versus vehicle-treated mice (ANOVA). (D) Effects of modulating vascular endothelial growth factor (VEGF) neutralizing antibody on tumor-associated angiogenesis at the end of the 14-day experimental period. Data are means ± sem for five mice. Control IgG: Mice receiving nonimmune IgG fraction. *p < 0.05 versus control IgG (ANOVA).
